Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment called STI-1492 for people who have a type of cancer called multiple myeloma that didn't get better with other treatments. The treatment is given through a vein in the arm.
This study is testing a new treatment called STI-1492 for people who have a type of cancer called multiple myeloma that didn't get better with other treatments. The treatment is given through a vein in the arm.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: